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As the core nationally representative health expenditure survey in the United States, the 
Medical Expenditure Panel Survey (MEPS) is increasingly being used by statistical 
agencies to track expenditures by disease.  However, while MEPS provides a wealth of 
data, its small sample size precludes examination of spending on all but the most 
prevalent health conditions.  To overcome this issue, statistical agencies have turned to 
other public data sources, such as Medicare and Medicaid claims data, when available.  
No comparable publicly available data exist for those with employer-sponsored 
insurance.  While large proprietary claims databases may be an option, the relative 
accuracy of their spending estimates is not known.  This study compared MEPS and 
MarketScan estimates of annual per person health care spending on individuals with 
employer-sponsored insurance coverage.  Both total spending and the distribution of 
annual per person spending differed across the two data sources, with MEPS estimates 10 
percent lower on average than estimates from MarketScan.  These differences appeared 
to be a function of both underrepresentation of high expenditure cases and 
underestimation across the remaining distribution of spending. 
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I. INTRODUCTION 
 
The Bureau of Economic Analysis (BEA) estimates that health care expenditures reached 
a share of 16 percent of gross domestic product (GDP) in 2006; the BEA is responding to 
this trend by working to develop an understanding of what the increased expenditure 
share represents.  Existing health measures in the National Income and Product Accounts 
(NIPAs) and the National Health Expenditure Accounts (NHEA) provide estimates on 
medical care that individuals purchase (i.e. doctor’s office visit or purchase of a drug) and 
how these purchases are financed (i.e. private insurance, government assistance, or out of 
pocket) (Sensenig and Wilcox (2001); Heffler et al. 2009).  While these estimates are 
useful for some purposes, they do not provide information on the particular disease being 
treated with each purchase.  Estimates of spending by disease are required for measuring 
the returns to treatment, whether or not the expenditure is beneficial, because that benefit 
depends on the particular disease one has.  For statistical agencies, spending by disease is 
required to properly measure real output, inflation and productivity for this important 
sector.  
 
In this light, efforts are now focused on measuring health expenditures, and creating 
subsequent health care price indexes, by disease (Rosen and Cutler 2007; Rosen and 
Cutler 2009).  To take on such a task requires data on the health conditions driving 
spending.  Initial efforts have turned to the national expenditure surveys for these data – 
most notably, the Medical Expenditure Panel Survey, or MEPS (Bradley et. al 2009).  
  3While MEPS provides a wealth of data, its small sample size precludes examination of 
spending on all but the most prevalent health conditions (Machlin et al. 2009; Mackie 
2009).  To overcome this issue, statistical agencies have turned to other public data 
sources when available.  For example, the Bureau of Economic Analysis is considering 
commercial claims data as a potential data source to measure medical care spending in 
the national accounts (Aizcorbe, Retus and Smith 2007).  
 
Despite the availability of quality data for patients covered by public programs, such as 
Medicare, there remains a lack of publicly available health care data on the largest 
segment of U.S. healthcare users: commercially insured patients and their families, who 
account for an estimated 68% of the total population.
1  For the commercially-insured 
population, multiple large proprietary databases exist; however, it is not clear how 
representative these data truly are.  Before we can confidently rely on these datasets for 
their sufficient sample size for disease-based pricing, we need to understand more 
generally how the heath care expenditures in these commercial databases compare with 
expenditures in MEPS.  While some differences are to be expected, if we understand 
these differences, we may be able to adjust for them. 
 
This paper compares the 2005 MEPS expenditure estimates of people with coverage 
through employers to the 2005 Thomson Healthcare MarketScan claims.  Our objectives 
are to better understand how the MarketScan database compares to MEPS and to identify 
areas requiring further investigation.   
                                                 
1 Estimate is current as of 2008 and is for people ages 18-64. 
http://www.cdc.gov/nchs/fastats/hinsure.htm 
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II.  STUDY DATA 
 
The data needed for our disease-based spending estimates must have both expenditures 
and information on patients’ illnesses.  While data are typically collected from providers 
at the encounter level, we need data at the patient level, including information on all the 
care received from the different types of providers.  For commercially-insured patients, 
the Medical Expenditure Panel Survey is the only government source for this type of 
information.  While the MEPS data are nationally representative, the small sample size 
precludes examination of health expenditures for all but the most prevalent health 
conditions (Machlin et al. 2009; Mackie 2009).   
 
Commercial claims data, on the other hand, provide much larger sample sizes but at the 
cost of representativeness (Mackie 2009; Rosen and Cutler 2009).  The claims data may 
be adjusted with sampling weights to provide nationally-representative estimates.   
 
A.  MEDICAL EXPENDITURE PANEL SURVEY (MEPS) 
 
The Medical Expenditure Panel Survey, which is conducted by the Department of Health 
and Human Services’ Agency for Healthcare Research and Quality (AHRQ) is a 
nationally representative survey of the health care utilization and expenditures of the 
civilian non-institutionalized U.S. population.  The survey sample is drawn from the prior 
year’s National Health Interview Survey (NHIS) sampling frame.  The survey uses an 
  5overlapping panel design in which the data are collected through a series of five rounds 
of interviews; the data from the overlapping panels are then used to produce annual 
estimates.  For each household surveyed, MEPS interviews a single respondent – the 
family member most knowledgeable about the entire household’s health and healthcare 
use (Zuvekas and Olin 2009a).  The sample includes approximately 15,000 families and 
35,000 individuals each year (Cohen, Cohen and Banthin 2009).  
 
MEPS provides both household and patient-level data on personal health care 
expenditures.  The survey contains data on health services used as well as the frequency 
with which households use them, their cost, and how they are paid for.  MEPS actually 
consists of a family of 3 interrelated surveys:  the Household Component (HC), the 
Medical Provider Component (MPC), and the Insurance Component (IC). The Household 
Component of the survey interviews individuals and families; the Medical Provider 
Component supplements this information by verifying prices, but not quantities, from 
medical providers and pharmacies.  The final component is the Insurance Component, 
which collects data from employers regarding the employers’ characteristics and the 
insurance they offer their employees (Sing et. al.2006; Zuvekas and Olin 2009b; and 
Cohen, Cohen and Banthin 2009). 
 
As a data source, MEPS has some key advantages over insurance claims data.  It is a 
well-known, nationally representative sample, and is generally regarded as a high-quality 
source of data on high-prevalence health conditions.  Another important strength of the 
MEPS data is its ability to directly link expenditures from all services (across all types of 
  6providers) to patient care events (Mackie 2009; Sing et. al. 2006).  Finally, MEPS is the 
only data set available to capture the expenditures of the uninsured (Cohen 2009). 
 
B.  MARKETSCAN 
  
The Thomson Healthcare MarketScan Research Databases are a nationwide convenience 
sample of patients from all providers of care.  MarketScan collects data from employers, 
health plans, and state-level Medicaid agencies and all claims have been paid and 
adjudicated.  Each enrollee has a unique identifier and can be identified at the three-digit 
zip code level
2.  This paper uses the Commercial Claims and Encounters Database 
portion of the MarketScan Databases, which includes health care utilization and cost 
records at the encounter level, with patient identifiers that may be used to sum 
expenditures to the patient level. 
 
The Commercial Claims and Encounters Database contains data from employer and 
health plan sources concerning medical and drug data for several million employer-
sponsored insurance (ESI)-covered individuals, including employees, their spouses, and 
dependents.  These enrollees obtain health care under fee-for-service plans, full and 
partially capitated plans, preferred and exclusive provider organizations, point of service 
plans, indemnity plans, health maintenance organizations, and consumer-directed health 
plans (Adamson, Chang and Hansen 2008).  
 
III.  METHODS  
                                                 
2 MarketScan User Guide: National Weights (White Paper) 
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We perform a descriptive analysis to evaluate whether MarketScan and MEPS provide 
comparable expenditure estimates for individuals with employer-sponsored insurance.  
This population makes up 91% of enrollees in private insurance plans. 
 
Our analytic files were constructed from the 2005 MEPS) and data on a similar 
population from MarketScan for 2005.  We identified individuals with ESI coverage in 
the MEPS data as individuals who reported having had coverage at any point in the 
calendar year through their current or past job, or through their union.  We include all the 
enrollees in the MarketScan database, since they all have ESI coverage.  For both 
datasets, we excluded patients 65 and over, as this population is measured by other 
datasets.  The final sample sizes included 15,300 MEPS respondents and 24.8 million 
individuals in the MarketScan sample, representing 165.05 million individuals with ESI 
coverage. 
 
A.  ENROLLMENT  
 
For each of the datasets, we created summary measures of enrollment using data from the 
enrollment files in the respective databases (the Full Year Consolidated Data File in 
MEPS and the Enrollment Summary file in the MarketScan data).  We grouped enrollees 
into demographic groups for age, gender and region.  The age and region variables from 
the MEPS are self-reported at various points of the year while those in the MarketScan 
data are only from the beginning of the 2005.      
  8 
We also applied statistical weights to each sample to obtain population estimates.  The 
MEPS data provides sample weights that take into account the complex sampling design 
of the survey making adjustments for survey nonresponse rates (Ezzati-Rice, Rohde and 
Greenblat 2000).  There are similar weights available for the MarketScan data; those 
weights are formed by comparing enrollment by age, gender, and region groups in the 
MarketScan convenience sample to those in the MEPS.  The age groups used in deriving 
the MarketScan weights were broader than those used in our study (0-18, 18-44, 45-64).  
So, although the weighted datasets should, by construction, give very similar enrollment 
counts for gender and region, we do not expect each dataset’s population estimates for 
enrollment for very granular age groups to be very similar.   
 
 
B.  EXPENDITURES 
 
We calculated total expenditures by summing expenditures that were reported by 
respondents, and then verified with providers (MEPS), or that were associated with 
claims submitted by enrollees (MarketScan).  We define expenditures as total gross 
payments to providers for services (rather than just out-of-pocket spending or the amount 
paid by the insurance company).  We included service categories that would yield 
comparable total spending estimates from the two datasets:  care at hospitals (inpatient, 
outpatient, and emergency room), office visits, and prescription drugs.  Because not all 
enrollees had prescription drug coverage, the MarketScan data likely underreports drug 
  9spending.  Inpatient care is self-reported in MEPS and identified in MarketScan as 
hospital care that involved a room and board charge.  The inpatient care category is 
essentially acute care:  the MEPS sampling frame excludes individuals residing in long-
term care and the MarketScan data contain very few claims from long-term facilities.     
 
 IV. STUDY FINDINGS 
 
A.  ENROLLMENT 
 
Table 1 illustrates that sampling weights can be applied to convenience samples to obtain 
better population estimates.  The first column of table 1 gives enrollment counts by 
demographic groups for the 24.8 million enrollees in the MarketScan sample; the second 
column does the same for the 15,300 individuals in the MEPS sample.  
 
The population estimates derived by applying the MarketScan weights are shown in the 
third column.  The distribution of age groups was similar between the sample and 
estimated population (columns 1 and 3), but the gender and region distributions were 
quite different.  The percent of enrollees that were female is about 50 percent in the 
population estimate, or two percent lower than the percent in the sample.  The percentage 
of enrollees living in the South and West regions was lower in the population estimates (a 
combined 56 percent of enrollees) than in the sample (70 percent of the enrollees).   
 
  10The MarketScan estimates for the distribution of enrollees in the population were very 
similar to those derived from the MEPS data (columns 3 and 4).   
 
B.  EXPENDITURES 
 
Applying weights to these samples did not provide very similar population estimates for 
total spending.  Estimated total spending according to the MarketScan data was about 10 
percent higher than that from the MEPS data ($453 billion and $408 billion, 
respectively).  As shown in table 2, the differences were not uniform across demographic 
groups. For example, the MarketScan estimate of total spending by males was 15 percent 
higher than MEPS and 8 percent higher for females.  These differences arose from 
differences in either the proportion of enrollees that were treated or the average 
expenditures for those patients.    
 
The per person spending distributions varied across the two data sources as well.  The 
MarketScan estimate for mean annual per person spending was higher than that in MEPS:  
$2,740 (with a 95% confidence interval of $2735 to $2745) in MarketScan and $2,472 
(with a 95% confidence interval of $2314 to $2629) in MEPS.  Excluding enrollees with 
zero spending magnified the differences in mean spending to about $500 per patient 
(from less than $300 for per patient).  The distribution of annual per person spending in 
each data source shown in Figure 1 demonstrates that these differences existed at most 
points in the distribution.   
 
  11Focusing on the right tail of the distribution, in the MEPS data, the maximum annual 
spending per patient was around $345,000 dollars while the maximum spending per 
patient in the MarketScan data was $4 million dollars.  Figure 2 shows the considerable 
differences across the two data sources in the distribution of spending in the top 5
th 
percentile of spenders.  The higher spending at the tail end of the distribution in the 
MarketScan data came from a relatively small number of patients (20,000, or less than 
1% of the total) that had spending higher than the highest spender reported in the MEPS 
data:  $345,882.  When we excluded these high spenders from the claims data, mean per 
patient spending remained higher in the MarketScan data than in the MEPS data ($3,465 




We compared 2005 MEPS health expenditure estimates for people with employer-
sponsored insurance to the spending estimates from 2005 MarketScan claims data for a 
large, convenience sample of individuals with ESI.  We found that MEPS underestimated 
expenditures in the ESI population, particularly at the high end of the expenditure 
distribution.  Truncating the MarketScan spending distribution, the differences narrowed 
somewhat but MEPS continued to underestimate spending relative to MarketScan, 
suggesting that there is also some ‘across the board’ underreporting of service use (and 
associated expenditures) in MEPS.  This persistent deviation is despite a likely 
undercount in the MarketScan data for prescription drugs (since not all enrollees had drug 
coverage).   
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Our finding that MEPS underestimates annual expenditures for individuals with ESI is 
consistent with past research demonstrating MEPS’ underestimation of spending on other 
populations, including non-institutionalized Medicare beneficiaries (Zuvekas and Olin 
2009b; Zuvekas and Olin 2009a) and Medicaid enrollees (Mark et. al. 2003).  More 
broadly, these findings are consistent with MEPS’ known underestimation of NHEA 
personal health expenditures (Selden et. al. 2001; Sing et. al. 2006).  Further, as in these 
past studies, the results of the current study suggest that the underestimation of 
expenditures in MEPS is largely a function both of 1) underrepresentation of high 
expenditure cases, and 2) underestimation of spending on the remaining covered lives. 
 
The striking underrepresentation of high cost spenders in MEPS is likely due to multiple 
factors.
3  While the MEPS sampling frame excludes individuals residing in long-term 
care facilities, MEPS respondents living in the community can be institutionalized 
subsequent to their entry into the MEPS sample.  Yet, those MEPS respondents who 
leave the community for a health care institution (as well as other institutions) suspend 
their medical care utilization and expenditure reporting while institutionalized.  
Respondents who eventually return to the community are again eligible for participation 
and resume reporting medical utilization and spending (Agency for Healthcare Quality 
and Research 2005).  Still, a vast gap in these individuals’ spending remains.  Hospital 
expenditures may also be underestimated because MEPS treats hospitalizations longer 
                                                 
3 A very similar problem arises when forming estimates for wealth, another variable with a highly skewed 
distribution.  Kennickell (2007) showed summary measure of wealth derived from the Survey of Consumer 
Finances administered by the Federal Reserve Board were significantly improved by their oversampling of 
wealthy households.    
  13than 45 days as an institutional stay, resulting in the exclusion from MEPS of the costs of 
these prolonged hospitalizations (Sing 2006).  In turn, for high cost individuals who are 
included in MEPS, total expenditures may be underestimated due to under-reporting of 
spending in the setting of major health changes.  For example, the survey may miss some 
of the high cost expenditures that occur just before a sampled person dies or is 
institutionalized.  Finally, there is some evidence that individuals using such services as 
renal dialysis clinics, outpatient alcohol treatment, and family planning centers, are not 
only underreported by households, but these households are not likely to be surveyed at 
all (Selden et al 2001).  To the extent these are high cost patients (certainly, dialysis 
patients are), this will further reduce the representation of high cost individuals in MEPS.   
  
Even after accounting for the poor capture of very high cost patients, MEPS 
underestimates spending relative to MarketScan data.
4 These differences could be caused 
by several different factors.  The accuracy of survey estimates are inseparably linked to 
the underlying survey design and response rates; errors may arise from sampling bias, 
non-response bias, attrition, and any of a number of other measurement errors (Cohen 
2003).  Underreporting of health services utilization is also a matter of import.  A recent 
review of 42 studies identified underreporting as the most common problem affecting the 
accuracy of self-reported utilization data (Bhandari and Wagner 2006).  While MEPS has 
the Medical Provider and Pharmacy Components to verify household reported costs, it 
does not use these components to verify the quantity of services utilized; the household 
                                                 
4 A similar problem arises with other expenditure surveys.  See Garner, Janini, Passero, Paskiewicz and 
Vendemia (2006) for a discussion of the issues in the context of the Consumer Expenditure Survey 
administered by the Bureau of Labor Statistics.   
  14reports are the sole source of quantity data, and underreported quantities will miss the 
corresponding spending (Zuvekas and Olin 2009b).   
 
MEPS may underestimate spending to a greater degree in some service categories than 
others.  For example, laboratory studies are one such source of underestimation.  MEPS 
captures expenditures for laboratory studies billed by physicians offices and outpatient 
care centers.  However, laboratory services that are billed independently - by the 
laboratories themselves – are not captured in MEPS (Selden et. al. 2001).  In addition, 
due to complex payment structures and third-party payers, household reports are likely to 
be inaccurate and surveys of providers and pharmacies do not cover all services, 
requiring costs to be imputed for certain services.  As with any imputation, this presents 
problems of both random and nonrandom error in the expenditure data (Zuvekas and Olin 
2009b).    
 
This study had some limitations of note.  First, while we attempted to make the MEPS 
and MarketScan ESI populations as comparable as possible, some differences may have 
remained.  MEPS is a relatively small sample, but should be nationally representative 
once weights are applied to account for sample design and nonresponse rate.  The 
enrollee counts in the MarketScan data can also be made representative by applying 
weights; however, some notable differences remained in the weighted data.  The  age 
profiles of the MarketScan-based population estimates differed somewhat from those 
from the MEPS.  Further, a lower proportion of MarketScan enrollees submitted claims 
  15than in MEPS (78% versus 81%).
5 Our findings beg the question of how best to combine 
the power (or sample size) of the MarketScan claims databases with the 
representativeness of the MEPS household surveys.  If differences between the two data 
sources were uniform across the distribution of spending, statistical adjustments could 
readily be made to correct the expenditures in both.  However, the expenditure 
differences are substantially greater at the high end of the spending distribution and more 




In conclusion, we found that, for individuals with employer-sponsored insurance, MEPS 
underestimates health care expenditures relative to MarketScan.  This appears to be a 
result of underrepresentation of high cost spenders, as well as a more general 
underestimation of spending across the distribution of health care expenditures in MEPS.  
With the rapid pace of change in the financing and delivery of health care, the demand 
for more clinically-nuanced measures of health care productivity will be critical for 
policymaking and planning.  To provide these estimates, statistical agencies will 
increasingly rely on different sources of national expenditure data.  The increased sample 
size provided by MarketScan data will allow for more clinically detailed expenditure 
estimates, however, the differences between this proprietary claims database and the 
comparable population in MEPS suggest the need for additional research focused on 
reconciling key differences. 
                                                 
5 Some of this difference might be explained by lack of prescription drug coverage for patients in the 
MarketScan sample.   
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ESI Population Estimates 
  MarketScan       MEPS            MarketScan        MEPS        
                 
Number of Enrollees  24.8 mil  15,300     165.1 mil     165.0 mil 
          
0 to 4 years  7.1 6.4    6.9    6.4 
5 to 17 years  19.2 20.1    18.6    18.6 
18 to 24 years  9.9 8.7    9.4    8.8 
25 to 44 years  31.6 33.8    33.5    33.9 
45 to 64 years  32.3 30.9    31.5    32.3 
Total  100%  100%    100%     100% 
            
            
Male  48.2 49.1    50.1    50.1 
Female  51.8 50.9    49.9    49.9 
Total  100%  100%    100%     100% 
            
            
Northeast  9.5 17.1    19.9    19.9 
Midwest  20.2 21.8    23.8    23.7 
South  45.4 36.5    34.0    34.1 
West  24.9 24.5    22.3    22.3 
Total  100%  100%    100%     100% 
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Table 2.  Differences in Spending for NonElderly Individuals Enrolled in ESI 
Plans, 2005  
 MarketScan    MEPS    Ratio 
          (1)/(2) 
               
0 to 4 years  $20.8    $14.4    1.44 
5 to 17 years  $30.3    $33.3    0.91 
18 to 24 years  $19.8    $17.3    1.14 
25 to 44 years  $121.6    $122.7    0.99 
45 to 64 years  $260.4    $220.2    1.18 
Total $452.9    $408.0    1.11 
          
          
Male  $251.9    $233.1    1.08 
Female  $201.0    $174.9    1.15 
Total $201.0    $174.9    1.15 
          
          
Northeast  $89.7    $77.4    1.16 
Midwest  $122.4    $112.2    1.09 
South  $162.1    $132.5    1.22 
West  $78.6    $85.9    0.92 
Total $452.9    $408.0    1.11 
Note:  All Estimates are Weighted     
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Table 3. Mean Annual Spending for ESI Enrollees, 2005 
  MarketScan   MEPS 
      
Enrollees in Sample  24.8 mil     15,300 
Estimated Population  165.1 mil    165.0 mil 
Percent with Spending  71.5%     80.8% 
      
Mean Annual Spending      
All Enrollees  $2,740     $2,472 
  (2.4)   (80.4) 
Enrollees with nonzero spending  $3,568     $3,045 
  (3.1)   (98.2) 
Truncated spending*  $3,465     $3,045 
   (2.4)    (98.2) 
Note: Standard errors are in parentheses. 
* Spending is truncated at highest MEPS expenditure. 
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